职称：教授
学历：博士
E-mail：zhuhaichuan@hbut.edu.cn
研究方向：血液肿瘤与细胞治疗
祝海川，教授，博士生导师，北京大学博士，湖北省杰出青年，湖北省楚天学者，武汉东湖高新“3551”光谷创新人才，武汉东湖高新“3551”光谷青年人才，湖北省博士后优秀人才跟踪支持计划入选者。主要研究方向为白血病的形成、维持机制及CAR-T肿瘤免疫治疗新技术的开发及产业化。主持国自然科学基金和湖北省重大专项等基金15项。截至目前以通讯作者（含共同）发表包括Nature immunology、Cell metabolism、Nature Cancer、Molecular therapy、Journal of Hematology & Oncology等论文40余篇，总引用超2000次，授权专利10项，完成或参与产业转化项目3项，参与研发、申报并获批anti-CD99 CAR-T细胞注射液IND I类新药批件。
教育及工作经历：
2025.07-至今 bwi437官网 437必赢会员中心 教授博士生导师
2019.07-2025.06武汉科技大学 生命科学与健康学院 博士后、副教授
2014.09-2019.07北京大学前沿交叉研究院整合生物学（导师：吴虹教授）博士
2010.09-2013.07湖北大学生命科学学院 生物化学硕士
2006.09-2010.07武昌理工学院生命科学学院生物工程学士
主要获奖：
1. 第十四届“挑战杯”中国大学生创业计划竞赛，国家金奖，1/4，2024
2. 第十三届“桃战坏”中国大学生创业计划竞赛，国家银奖，1/4，2023
3. 中国国际大学生创新大赛，全国铜奖，1/4，2024
4. 发明创业成果奖，省部级，二等奖，3/5，2024
5. 科创中国·湖北科技经济融合优秀项目，二等奖，排名第二，2023
6. 科创中国·湖北科技经济融合优秀项目，三等奖，排名第二，2023
7. 湖北省第十二届“挑战杯·中国银行”大学生创业计划竞赛，省级金奖，1/4
8. 数字中国创新大赛·智慧医疗赛道华中赛区决赛，省赛一等奖，1/1
近五年完成的主要论文(#共同第一作者, *通讯作者)：
1.Long Chen#, Anqi Ren#, Hangyu Chen, Qifang Wu, Yuan Zhao, Zijian zhang, Tongcun Zhang, Wu Zhong*, Jian Lin*,Haichuan Zhu*,Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL.J Hematol Oncol.2023.16(1):113.
2.Jiangzhou Shi#, Zijian Zhang#, Hong Cen#, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin, Kunyu Yang, Tongcun Zhang*,Haichuan Zhu*. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.J Hematol Oncol .2021.14, 162.
3.Zijian Zhang，Qifang Wu，Anqi Ren，Qian Chen，Jiangzhou Shi，Jiapeng Li，Xiyu Liu，Zhijie Zhang，Yuzhe Tang，Yuan Zhao，Ningning Yao，Xiaoyu Zhang，Changpeng Liu，Ge Dong，Jiaxuan Zhao，Meijun Xu，Yunqiang Yue，Jia Hu，Fan Sun，Yu Liu，Qilin Ao，Fuling Zhou，Hong Wu，Tongcun Zhang*，Haichuan Zhu*.ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming." Acta Pharmacologica Sinica .2023.1-14.
4.Jie Cheng#, Yifeng Xiao#, Ting Peng#, Zijian Zhang#, You Qin#, Yuqian Wang, Jiangzhou Shi, Jinxin Yan, Zihao Zhao, Liangtao Zheng, Zhijun He, Jianwei Wang, Zemin Zhang*, Cheng Li*, Haichuan Zhu*, Peng Jiang*. (2025). ETV7 limits the antiviral and antitumor efficacy of CD8+ T cells by diverting their fate toward exhaustion. Nature Cancer, 1-19.
5.Jie Chen#, Jinxin Yan#, Jiangzhou Shi#, Ying Liu, Yuzhe Li, Lina Zhao, Yinglin Zhou, Tongcun Zhang, Qiangfeng Cliff Zhang, Xinxiang Zhang*,Haichuan Zhu*, Peng Jiang*.Cancer-cell-derived fumarate suppresses the antitumorcapacity of CD8+ T cells in the tumor microenvironment,Cell Metabolism，2023.35，1-18.
6.Jie Shi#,Zijian Zhang#,Hsin-Yi Chen#,Yingmeng Yao,Shanwen Ke,Kechun Yu,Jiangzhou Shi,Xiangling Xiao,Chuan He,Bolin Xiang,Yishuang Sun,Minling Gao,Xixin Xing,Haisheng Yu,Xiyong Wang,Wei-Chien Yuan,Bugi Ratno Budiarto,ShihYu Chen,Tongcun Zhang,YRu Lee*,Haichuan Zhu*,Jinfang Zhang*.Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR T cell therapy. Molecular Therapy,2025.
7.Bolin Xiang#, Meiling Zhang#, Kai Li#, Zijian Zhang#, Yutong Liu, Minling Gao, Xiyong Wang, Xiangling Xiao,Yishuang Sun, Chuan He, Jie Shi, Hongzeng Fan, Xixin Xing, Gaoshan Xu, Yingmeng Yao , Gang Chen*,Haichuan Zhu*,Chengqi Yi*，Jinfang Zhang*. The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to control antitumor immunity. Nature Immunology,2025, 1-13.
8.Lu Yang#, Fenglin Chen#,Haichuan Zhu#, Yang Chen, Bingjie Dong, Minglei Shi, Weitao Wang, QianJiang, Leping Zhang, Xiaojun Huang*, Michael Qi Zhang*, Hong Wu*, 3D genome alterations associated with dysregulated HOXA13 expression in high-risk T-lineage acute lymphoblastic leukemia. Nature Communications, 2021. 12(1), 1-12.
9.Nuo Xu#, Zhaoya Gao#, Deyan Wu#, Hangyu Chen#, Zijian Zhang#, Lei Zhang, Yuchen Wang, Xuyang Lu, Xu Yao, Xuelan Liu, Yi-You Huang, Meiying Qiu, Sen Wang, Jinqiang Liang, Can Mao, Feng Zhang, Huimin Xu, Yujiao Wang, Xian Li, Zhexin Chen, Dandan Huang, Jingyi Shi, Wensheng Huang, Fuming Lei, Zeruo Yang, Long Chen, Chuan He, Haichuan Zhu*, Hai-Bin Luo*, Jin Gu*, Jian Lin*. 5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target.Clin Transl Med. 2025 Feb;15(2): e70189.
10.Haichuan Zhu,Liuzhen Zhang, Yilin Wu, Bingjie Dong, Weilong Guo, Mei Wang, Lu Yang, Xiaoying Fan, Yuliang Tang, Ningshu Liu, Xiaoguang Lei, Hong Wu*, T-ALL leukemia stem cell'stemness' is epigenetically controlled by the master regulator SPI1.Elife. 2018;7: e38314).
